ZURICH (AFX) - Novartis AG said data from the extension to a phase II study to 18 months support the significant effects of FTY720, the Swiss company’s oral multiple sclerosis drug, showing sustained efficacy and good tolerability.
ZURICH (AFX) - Novartis AG said data from the extension to a phase II study to 18 months support the significant effects of FTY720, the Swiss company’s oral multiple sclerosis drug, showing sustained efficacy and good tolerability.
